Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jessica Teh"'
Autor:
Madhura S Mehta, Sonia C Dolfi, Roman Bronfenbrener, Erhan Bilal, Chunxia Chen, Dirk Moore, Yong Lin, Hussein Rahim, Seena Aisner, Romona D Kersellius, Jessica Teh, Suzie Chen, Deborah L Toppmeyer, Dan J Medina, Shridar Ganesan, Alexei Vazquez, Kim M Hirshfield
Publikováno v:
PLoS ONE, Vol 8, Iss 7, p e69851 (2013)
Several epidemiological studies have suggested a link between melanoma and breast cancer. Metabotropic glutamate receptor 1 (GRM1), which is involved in many cellular processes including proliferation and differentiation, has been implicated in melan
Externí odkaz:
https://doaj.org/article/b78fd09196ca453fa1e9066739b6e8fd
Autor:
Jessica Teh, Elizabeth Bortolon, Jennifer Pizzano, Melissa Pannone, Sean Landrette, Richard Gedrich, Ian Taylor
Publikováno v:
Cancer Research. 83:3075-3075
ARV-471 is a selective, orally bioavailable PROteolysis-TArgeting Chimera (PROTAC®) small molecule that induces wild-type and mutant estrogen receptor (ER) alpha degradation via the ubiquitin-proteasome system. ARV-471 demonstrates superior ER degra
Autor:
Jessica Teh, Shannon Bessonett, Wendy Wu, Christopher Kuhlberg, Alissa Wynne, Sean Landrette, Monica Andreoli, Elizabeth Bortolon, Jennifer Pizzano, Richard Gedrich, Ian Taylor
Publikováno v:
Cancer Research. 83:432-432
ARV-471 is an orally bioavailable cereblon (CRBN)-based PROteolysis-TArgeting Chimera (PROTAC®) small molecule that demonstrates superior ER degradation and anti-tumor activity compared to fulvestrant in endocrine sensitive and resistant xenograft m
Autor:
Szu-Chin Fu, Norbert Kraut, Rachel L Mendes, Marco H. Hofmann, Michael Gmachl, Peter Ettmayer, Katharina Schipany, Juergen Ramharter, Joseph R. Marszalek, Michael P. Sanderson, Tobias Wunberg, Fabio Savarese, Mark Petronczki, Timothy P. Heffernan, Thomas Gerstberger, Jark Böttcher, Mark Pearson, Dana-Adriana Botesteanu, Daniel Gerlach, Dirk Kessler, Franziska Schachinger, Klaus Rumpel, Jessica Teh, Jonathan O’Connell, Christiane Kofink, Heribert Arnhof, Simone Lieb, Jürgen Moll, Christopher P. Vellano, Nikolai Pototschnig, Andreas Zoephel, Darryl B. McConnell, Francesca Trapani
Publikováno v:
Cancer discovery. 11(1)
KRAS is the most frequently mutated driver of pancreatic, colorectal, and non–small cell lung cancers. Direct KRAS blockade has proved challenging, and inhibition of a key downstream effector pathway, the RAF–MEK–ERK cascade, has shown limited
Autor:
Daniel Gerlach, Thomas Gerstberger, Dirk Kessler, Tobias Wunberg, Jessica Teh, Francesca Trapani, Marco H. Hofmann, Christopher P. Vellano, Szu-Chin Fu, Mark Pearson, Joseph R. Marszalek, Heribert Arnhof, Timothy P. Heffernan, Norbert Kraut, Peter Ettmayer, Michael Gmachl, Christiane Kofink, Klaus Rumpel, Dana-Adriana Botesteanu, Darryl B. McConnell, Juergen Ramharter
Publikováno v:
Cancer Research. 80:1091-1091
KRAS is the most frequently mutated oncogene with high prevalence of alterations in pancreatic, colorectal, and non-small cell lung tumors. The alleviation of negative feedback control of KRAS activity upon downstream inhibition has limited the clini
Autor:
Szu-Chin Fu, Christiane Kofink, Jonathan O’Connell, Thomas Gerstberger, Mark Pearson, Marco H. Hofmann, Juergen Moll, Heribert Arnhof, Jürgen Ramharter, Fabio Savarese, Daniel Gerlach, Jessica Teh, Dana-Adriana Botesteanu, Joseph R. Marszalek, Michael Gmachl, Timothy P. Heffernan, Rachel L Mendes, Michael P. Sanderson, Peter Ettmayer, Dirk Kessler, Klaus Rumpel, Tobias Wunberg, Norbert Kraut, Francesca Trapani, Darryl B. McConnell, Christopher P. Vellano
Publikováno v:
Molecular Cancer Therapeutics. 18:PL06-01
KRAS is the most frequently mutated oncogene with high prevalence in pancreatic, colorectal, and non-small cell lung tumors. KRAS signaling is tightly regulated and various factors, including negative feedback pathways have limited the clinical effic
Autor:
Jessica, Teh, Suzie, Chen
Publikováno v:
Wiley interdisciplinary reviews. Membrane transport and signaling. 1(2)
G-protein coupled receptors (GPCR) represent a class of therapeutic targets that have been widely exploited for drug designs and development. Metabotropic glutamate receptors (mGluRs) belong to Class C GPCRs and are predominantly involved in maintain